Alamartine 1994a.

Study characteristics
Methods	Publication type: full article Study design: parallel RCT Follow‐up period: not reported Duration of study: not reported
Participants	Country: France Setting: not reported ICU: yes Number: treatment group (7); control group (6) Mean age ± SD: not reported Sex (M/F): not reported Mean severity ± SD (APACHE 2 score): treatment group (24 ± 6); control group (20 ± 4) Cause of AKI: not reported Inclusion criteria: not reported Exclusion criteria: not reported
Interventions	Treatment group CVVHDF with convection that was obtained by a 2 L/hour pre‐dilutional infusion Control group CVVHD without convection
Outcomes	None of our prespecified outcomes of interest were reported
Notes	Funding source: Fresenius‐Smad
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	Unclear risk	Study protocol was not available; none of our prespecified outcomes were reported
Other bias: baseline imbalance	Low risk	We did not identify any substantial differences between groups
Other bias: co‐interventions	High risk	The amount of heparin use in the two groups was substantially different